



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO.  | FILING DATE    | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |
|--|----------------|----------------------|-------------------------|------------------|
| 09/676,249   | 09/29/2000     | Kendall Wayne        | PC10555A                | 1131             |
| 75   | 590 03/27/2002 |                      |                         |                  |
| Paul H Ginsburg  |                |                      | EXAMINER                |                  |
| Pfizer Inc 235 East 42nd Street 20th Floor New York, NY 10017-5755 |                |                      | SWARTZ, RODNEY P        |                  |
|  |                |                      | ART UNIT                | PAPER NUMBER     |
|  |                |                      | 1645                    | a                |
|  |                |                      | DATE MAILED: 03/27/2002 |                  |

Please find below and/or attached an Office communication concerning this application or proceeding.

| · · · · · ·  | Application No.  | Applicant(s)   |  |  |  |
|--|--|--|--|--|--|
|  | 09/676,249   | WAYNE ET AL.   |  |  |  |
| Office Action Summary  | Examiner   | Art Unit   |  |  |  |
|  | Rodney P. Swartz, Ph.D.  | 1645   |  |  |  |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply   |  |  |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a rep If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status | 136(a). In no event, however, may a repoly within the statutory minimum of thirty (I will apply and will expire SIX (6) MONTHE, cause the application to become ABAI | ly be timely filed  (30) days will be considered timely.  HS from the mailing date of this communication.  NDONED (35 U.S.C. § 133). |  |  |  |
| 1) Responsive to communication(s) filed on   | ·  |  |  |  |  |
| 2a) ☐ This action is <b>FINAL</b> . 2b) ☑ T  | his action is non-final.   | •  |  |  |  |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.   |  |  |  |  |  |
| Disposition of Claims  |  |  |  |  |  |
| 4) Claim(s) 1-11 and 18-33 is/are pending in the application.  |  |  |  |  |  |
| 4a) Of the above claim(s) is/are withdrawn from consideration.   |  |  |  |  |  |
| 5) Claim(s) is/are allowed.  |  |  |  |  |  |
| 6) Claim(s) is/are rejected.   |  |  |  |  |  |
| 7) Claim(s) is/are objected to.  | and/ar aloation to suitam ont  |  |  |  |  |
| 8) Claim(s) <u>1-11, 18-33</u> are subject to restriction and/or election requirement.  Application Papers   |  |  |  |  |  |
| 9) The specification is objected to by the Examiner.   |  |  |  |  |  |
| 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.   |  |  |  |  |  |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  |  |  |  |  |  |
| 11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.  |  |  |  |  |  |
| If approved, corrected drawings are required in reply to this Office action.   |  |  |  |  |  |
| 12) The oath or declaration is objected to by the Examiner.  |  |  |  |  |  |
| Priority under 35 U.S.C. §§ 119 and 120  |  |  |  |  |  |
| 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  |  |  |  |  |  |
| a) ☐ All b) ☐ Some * c) ☐ None of:   |  |  |  |  |  |
| 1. Certified copies of the priority documents have been received.  |  |  |  |  |  |
| 2. Certified copies of the priority documents have been received in Application No   |  |  |  |  |  |
| <ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>  |  |  |  |  |  |
| 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).   |  |  |  |  |  |
| a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.   |  |  |  |  |  |
| Attachment(s)  |  |  |  |  |  |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)  | 5) Notice of In  | ummary (PTO-413) Paper No(s) formal Patent Application (PTO-152)   |  |  |  |

Application/Control Number: 09/676,249

Art Unit: 1645

## **DETAILED ACTION**

## **Election/Restriction**

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-11, drawn to protein, classified in class 424, subclass 264.1.
  - II. Claims 18-28, drawn to DNA, host cell, classified in class 536, subclass 23.7.
  - III. Claims 29-31, drawn to method of making protein, classified in class 435, subclass 69.1.
- IV. Claims 32-33, drawn to method of treatment, classified in class 424, subclass 9.2. The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are drawn to structurely and functionally distinct molecules, i.e., amino acids and nucleic acids.

Inventions I and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the protein of Invention I can be isolated from naturally occurring *M. hyopneumoniae*.

Inventions I and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP

Application/Control Number: 09/676,249

Art Unit: 1645

§ 806.05(h)). In the instant case, the protein of Invention I can be used in assays for detection of infection by *M. hyopneumoniae*.

Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the DNA of Invention II can be used in hybridization probe assays for detection of infection by *M. hyopneumoniae*.

Inventions II and IV are unrelated inventions directed to structurely and functionally distinct molecules. Invention II is directed to nucleic acids, Invention IV to amino acids.

Inventions III and IV are two distinct methodologies utilizing different reagents and resulting in different end points.

Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and because while the searches may overlap, the searches are not coextensive, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

Application/Control Number: 09/676,249

Art Unit: 1645

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(I).

2. Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Rodney P. Swartz, Ph.D., whose telephone number is (703) 308-4244. The

examiner can normally be reached on Monday through Thursday from 5:30 AM to 4:00 PM EST.

If attempts to reach the Examiner by telephone are unsuccessful, the examiner's

supervisor, Lynette F. Smith, can be reached on (703)308-3909. The facsimile telephone number

for the Art Unit Group is (703)308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the group receptionist whose telephone number is (703)308-0196.

ODNEY P SWARTZ, PH.D.

Page 4

Art Unit 1645

March 27, 2002